A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

Trial Profile

A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TOWER
  • Sponsors Amgen
  • Most Recent Events

    • 19 Jun 2018 Based on the OS data from this trial, the European Commission (EC) has granted a full marketing authorization for BLINCYTO (blinatumomab) in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Approval is valid in all European Union (EU) and European Economic Area (EEA)-European Free Trade Association (EFTA) states (Norway, Iceland and Liechtenstein).
    • 17 Jun 2018 Results comparing efficacy of Blinatumomab versus Inotuzumab Ozogamicin by taking patient data from TOWER and INO-VATE studies, presented at the 23rd Congress of the European Haematology Association.
    • 08 May 2018 Results assessing the impact of blinatumomab on health-related quality of life (n=342), published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top